Evidence Hub

A Case Report of IgA‐κ Type Multiple Myeloma Complicated With Hyperlipidemia

Jie Li, Jia-Shan Zhao, Songyun Wang, Rundong Wu, Shu-Yi Duan, Hui-Rui Wang

Clinical Case Reports, 2025

3 citations

Abstract

In the majority of cases, patients with multiple myeloma (MM) generally exhibit normal or decreased blood lipid levels. However, a minority of cases demonstrate the significant role of M protein in elevated lipid levels, particularly in the close association between IgA type MM and hypertriglyceridemia and hypercholesterolemia. Here, we report a case of IgA‐κ type MM with concurrent hyperlipidemia, wherein the patient presented with elevated lipid levels upon admission: total cholesterol of 10.44 mmol/L (normal range: 2.8–5.6 mmol/L) and triglycerides of 28.45 mmol/L (normal range: 0.45–1.70 mmol/L). The patient also had concurrent multiple myeloma and was treated with the PCD regimen along with lipid‐lowering measures, hydration, alkalization, liver protection, and symptomatic supportive care, and showed a significant improvement in symptoms and was discharged. The aim was to explore the relationship between IgA type MM and hyperlipidemia, and then provide guidance for clinical diagnosis and treatment.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free